[1-(5-Methylisoxazol-3-yl)piperidin-4-yl]acetic acid trifluoroacetate → N-[6-Chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-yl]-2-[1-(5-methylisoxazol-3-yl)piperidin-4-yl]acetamide Trifluoroacetate

HRID 541729Notes

Reaction equation

HRID 541729 reaction equation
Cl.Cl.[Cl:3][C:4]1[CH:5]=[N:6][C:7]2[NH:8][C:9]3[CH:10]=[CH:11][CH:12]=[C:13]([CH:26]=3)[CH2:14][CH2:15][C:16]3[CH:24]=[C:20]([NH:21][C:22]=1[N:23]=2)[CH:19]=[CH:18][C:17]=3[NH2:25].[F:27][C:28]([F:33])([F:32])[C:29]([OH:31])=[O:30].[CH3:34][C:35]1[O:39][N:38]=[C:37]([N:40]2[CH2:45][CH2:44][CH:43]([CH2:46][C:47](O)=[O:48])[CH2:42][CH2:41]2)[CH:36]=1>>[F:27][C:28]([F:33])([F:32])[C:29]([OH:31])=[O:30].[Cl:3][C:4]1[CH:5]=[N:6][C:7]2[NH:8][C:9]3[CH:10]=[CH:11][CH:12]=[C:13]([CH:26]=3)[CH2:14][CH2:15][C:16]3[CH:24]=[C:20]([NH:21][C:22]=1[N:23]=2)[CH:19]=[CH:18][C:17]=3[NH:25][C:47](=[O:48])[CH2:46][CH:43]1[CH2:42][CH2:41][N:40]([C:37]2[CH:36]=[C:35]([CH3:34])[O:39][N:38]=2)[CH2:45][CH2:44]1

Participants

3

Reactant 2

HCID 66880432[1-(5-Methylisoxazol-3-yl)piperidin-4-yl]acetic acid trifluoroacetateHCID 668960506-Chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-amine Dihydrochloride

Product 1

HCID 66896554N-[6-Chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-yl]-2-[1-(5-methylisoxazol-3-yl)piperidin-4-yl]acetamide TrifluoroacetateYield 8%

Procedure

The desired compound was prepared according to the procedure of Example A169, step B using 6-chloro2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa1(20),3(22),4,6,9(21),10,12,16,18-nonaen-12-amine dihydrochloride and [1-(5-methylisoxazol-3-yl)piperidin-4-yl]acetic acid trifluoroacetate as starting materials in 8% yield. LCMS for C29H31ClN7O2 (M+H)+: m/z=544.2.

Sources & evidence

ORD record
ord-c6c9578ea2624b98805d4f15d0143ff1
Source dataset
uspto-grants-2014_10
Patent number
US08871753B2

Reaction notes

Loading…